← Back to Screener
Cogent Biosciences, Inc. Common Stock (COGT)
Price$37.00
Favorite Metrics
Price vs S&P 500 (26W)120.20%
Price vs S&P 500 (4W)2.10%
Market Capitalization$6.05B
All Metrics
Book Value / Share (Quarterly)$3.95
P/TBV (Annual)2.25x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.65
Price vs S&P 500 (YTD)0.73%
Net Profit Margin (TTM)-264.08%
EPS (TTM)$-2.55
10-Day Avg Trading Volume2.17M
EPS Excl Extra (TTM)$-2.55
EPS (Annual)$-2.46
ROI (Annual)-99.89%
Net Profit Margin (5Y Avg)-407.35%
Cash / Share (Quarterly)$5.60
ROA (Last FY)-78.07%
EBITD / Share (TTM)$-2.62
ROE (5Y Avg)-59.00%
Operating Margin (TTM)-295.77%
Cash Flow / Share (Annual)$-1.65
P/B Ratio9.50x
P/B Ratio (Quarterly)8.49x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)257.21x
ROA (TTM)-68.45%
EPS Incl Extra (Annual)$-2.46
Current Ratio (Annual)14.23x
Quick Ratio (Quarterly)14.08x
3-Month Avg Trading Volume2.27M
52-Week Price Return772.37%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.52
P/S Ratio (Annual)768.23x
Asset Turnover (Annual)0.03x
52-Week High$43.73
Operating Margin (5Y Avg)-434.04%
EPS Excl Extra (Annual)$-2.46
CapEx CAGR (5Y)80.39%
Tangible BV CAGR (5Y)55.30%
26-Week Price Return128.95%
Quick Ratio (Annual)14.08x
13-Week Price Return-1.43%
Total Debt / Equity (Annual)0.35x
Current Ratio (Quarterly)14.23x
Enterprise Value$5,956.886
Asset Turnover (TTM)0.36x
Book Value / Share Growth (5Y)-11.46%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-950.57%
Cash / Share (Annual)$5.60
3-Month Return Std Dev49.87%
Net Income / Employee (TTM)$-1
ROE (Last FY)-99.89%
EPS Basic Excl Extra (Annual)$-2.46
Receivables Turnover (TTM)7.87x
Total Debt / Equity (Quarterly)0.35x
EPS Incl Extra (TTM)$-2.55
Receivables Turnover (Annual)7.87x
ROI (TTM)-81.02%
P/S Ratio (TTM)261.05x
Pretax Margin (5Y Avg)-407.35%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.66
Price vs S&P 500 (52W)737.27%
Year-to-Date Return4.87%
5-Day Price Return2.00%
EPS Normalized (Annual)$-2.46
ROA (5Y Avg)-49.41%
Net Profit Margin (Annual)-950.57%
Month-to-Date Return-3.22%
Cash Flow / Share (TTM)$-2.32
EBITD / Share (Annual)$-2.44
Operating Margin (Annual)-1044.47%
LT Debt / Equity (Annual)0.35x
ROI (5Y Avg)-59.00%
LT Debt / Equity (Quarterly)0.35x
EPS Basic Excl Extra (TTM)$-2.55
P/TBV (Quarterly)1.90x
P/B Ratio (Annual)8.49x
Pretax Margin (TTM)-264.08%
Book Value / Share (Annual)$3.95
Price vs S&P 500 (13W)-4.29%
Beta0.43x
P/FCF (Annual)384.36x
Revenue / Share (TTM)$0.00
ROE (TTM)-100.22%
52-Week Low$4.12
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.28
4.26
4.26
4.26
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
COGTCogent Biosciences, Inc. Common Stock | 261.05x | — | — | — | $37.00 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Cogent Biosciences develops precision therapies for genetically defined diseases. Its lead program, CGT9486, is a selective tyrosine kinase inhibitor targeting KIT mutations—specifically D816V mutations that drive Systemic Mastocytosis and exon 17 mutations found in advanced gastrointestinal stromal tumors (GIST). The company addresses significant unmet medical needs in these serious hematologic and oncologic conditions.